Overview

A Clinical Study of SHR-A1811 in the Treatment of HER2-positive Locally Advanced or Metastatic Biliary Tract Cancer

Status:
RECRUITING
Trial end date:
2028-09-01
Target enrollment:
Participant gender:
Summary
This study is an open, multicenter Phase II clinical trial to evaluate the efficacy and safety of the SHR-A1811 combination in HER2 positive patients with locally advanced or metastatic biliary tract cancer.
Phase:
PHASE2
Details
Lead Sponsor:
Suzhou Suncadia Biopharmaceuticals Co., Ltd.